W L Gore & Associates (Gore) has obtained the US Food and Drug Administration (FDA) approval of its GORE TIGRIS Vascular Stent to treat peripheral artery disease (PAD).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The GORE TIGRIS Vascular Stent is a third generation, self-expanding and dual-component stent featuring a fluoropolymer / nitinol design which has been designed to improve the anatomy conforming to the natural movement of the knee.

Its dual component structure is made from a single-wire nitinol stent with flexible and biocompatible fluoropolymer interconnections.

The stent can withstand biomechanical forces, such as extension, compression, flexion and torsion, without causing fractures in complex anatomies, namely the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

The US clinical study supporting the FDA approval demonstrated the usage of TIGRIS stent resulting in zero fractures.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Davis, California-based interventional cardiologist John Laird said: “The TIGRIS Vascular Stent has an innovative design that is very different from any of the other nitinol stents that we currently use.

“The extreme flexibility of this stent makes it well suited for the superficial femoral artery and proximal popliteal artery, and the delivery system is highly accurate.

"The precision offered by this flexible, dual component device allows for easy insertion and predictable clinical outcomes, even in challenging anatomy."

“The precision offered by this flexible, dual component device allows for easy insertion and predictable clinical outcomes, even in challenging anatomy.”

The device also features Gore's CBAS Heparin Surface which is a durable heparin bonding technology designed to inhibit thrombus formation, a common issue in both bare metal and drug-eluting stents.

The end-point covalent bonding attaches the heparin to the stent surface allowing the bioactive site to interact with the blood to help prevent clotting.


Image: GORE TIGRIS Vascular Stent. Photo: courtesy of Business Wire.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact